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Abstract
Introduction: Hydroxychloroquine (HCQ) is a common disease modifying therapy for the treatment of rheumatoid
arthritis (RA). Prior research suggests that HCQ may reduce the risk of diabetes mellitus in patients with RA. To
investigate the mechanism of this effect, we examined the effect of HCQ on insulin resistance, insulin sensitivity,
and pancreatic b-cell secretion of insulin in non-diabetic, obese subjects.
Methods: We recruited 13 obese, non-diabetic subjects without systemic inflammatory conditions for an open-
label longitudinal study of HCQ 6.5 mg per kilogram per day for six weeks. Subjects underwent an oral glucose
tolerance test at three time points: 0 weeks (pre-treatment with HCQ), 6 weeks (at the end of the HCQ treatment),
and 12 weeks (6 weeks post HCQ-treatment). The Matsuda Insulin Sensitivity Index (ISI), HOMA-IR, and HOMA-B
were compared across time-points.
Results: The mean age of the cohort was 49 years, 77% females and median body mass index was 36.1 kg/m
2.
After 6 weeks of HCQ therapy, ISI increased from a median (interquartile range) of 4.5 (2.3-7.8) to 8.9 (3.7-11.4) with
a p-value of 0.040, and HOMA-IR decreased from a median of 2.1 (1.6-5.4) to 1.8 (1.02-2.1) with a p-value of 0.09.
All these variables returned toward baseline at week 12.
Conclusion: HCQ use for 6 weeks in non diabetic obese subjects was associated with a significant increase in ISI
and trends toward reduced insulin resistance and insulin secretion. These data suggest that HCQ, a common
medication used to treat RA, possesses beneficial effects upon insulin sensitization. Further study of the insulin
sensitizing effects of HCQ in patients with RA is warranted.
Introduction
Individuals with several different rheumatic diseases
carry a greater risk of developing cardiovascular disease
(CVD)[1-4] . It is likely that the systemic inflammation
underpinning these conditions contributes to an
increased risk of CVD [5]. One possible link between
the systemic inflammation of rheumatic diseases and an
increased risk of CVD is worsening of insulin resistance.
Insulin resistance is a common risk factor for both CVD
and diabetes mellitus (DM) [6]. Insulin resistance refers
to impaired insulin sensitivity and glucose metabolism,
and commonly precedes development of DM [6]. Addi-
tionally, insulin resistance represents one facet of the
metabolic syndrome, a constellation of risk factors that
predict CVD events [1,2,7,8].
Insulin resistance occurs more frequently in systemic
rheumatic diseases, such as rheumatoid arthritis (RA)
and systemic lupus erythematosus (SLE) [9,10]. In rheu-
matic disease patients, systemic inflammation appears to
act directly on insulin and glucose metabolism through
elevated levels of TNFa and IL-6 [9,11-13]. Several phar-
macologic treatments for rheumatic diseases have been
associated with improvements in insulin and glucose
metabolism. Anakinra, an IL-1 antagonist, effectively
reduced glycated hemoglobin in patients with type 2 DM,
and TNFa antagonists have improved insulin resistance
in patients with RA or ankylosing spondylitis [11-14].
Hydroxychloroquine, a US Food and Drug Agency-
approved medication for SLE and RA, has also been
shown to improve glycated hemoglobin in patients with
poorly controlled type 2 DM [15,16]. A cross-sectional
study of CVD risk factors among women with SLE or RA
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during HCQ use [17]. In two large epidemiological stu-
dies of patients with RA, an association was noted
between HCQ use and a reduced risk of developing DM
[18,19]. Furthermore, animal models suggest that HCQ
may retard insulin degradation [20,21]. However, we find
no human studies in the published literature that exam-
ine the effect of HCQ on insulin and glucose metabolism.
In light of this background, we pursued a pilot study
among non-diabetic obese subjects without a known
systemic inflammatory condition. We assessed HCQ’s
effect on insulin sensitivity and secretion during a short-
term study and hypothesized that insulin sensitivity
would improve during HCQ administration.
Materials and methods
Study population
Thirteen adult subjects were recruited from the commu-
nity. All aspects of this study were approved by the Part-
ners Institutional Review Board (IRB) at Brigham and
Women’s Hospital. Additionally, each patient signed an
informed consent form that was obtained according to
the Declaration of Helsinki and approved by the IRB at
Brigham and Women’s Hospital. All had a body mass
index (BMI) ≥ 30 kg/m
2 and no history of DM. Subjects
were excluded if there was current oral corticosteroid
use, or a history of neuromuscular disease, psoriasis,
chronic inflammatory intestinal disorders or eye disease
(with the exception of cataracts or glaucoma). Addition-
ally, confirmation of normal liver and kidney function
testing was required before drug administration. The
Partners HealthCare System IRB approved all aspects of
this study.
Intervention
Subjects were administered a six-week course of HCQ
(6.5 mg/kg) over the course of the study. At the baseline
visit, subjects were given a three-week supply of HCQ and
complete instructions on daily administration. During the
safety visit (week 3 following baseline), subjects were given
their second three-week supply of HCQ. Subjects were
then instructed to stop taking HCQ at week 6, and return
any unused study drug to the study staff. A record was
kept of each subject’s pill counts and reminder phone calls
were made to keep subjects as compliant as possible. All
subjects were closely monitored and in contact with study
staff throughout the twelve-week protocol.
Study procedures and data collection
After eligibility was confirmed through screening proce-
dures, all subjects completed a total of four study visits
and two phone conversations with study staff over the
course of twelve weeks (see Additional file 1 for schedule
of visits). At the baseline visit, the first of three oral
glucose tolerance tests (OGTT) was performed with
blood samples collected every 30 minutes for 120 min-
utes to measure the primary outcome of interest, insulin
sensitivity index (ISI). The ISI was calculated based on
the equation of Matsuda [22] and the area under the
curve of insulin and homeostasis model assessment-esti-
mated insulin resistance (HOMA-IR) were also calcu-
lated [23]. The formulas for each of these calculations are
as follows.
Matsuda insulin sensitivity index:
ISI(Matsuda) =
10000
√
G0 × I0 × Gmean × Imean
ISI, insulin sensitivity index; G0, fasting plasma glucose
(mg/dL); I0, fasting plasma insulin (mIU/L); Gmean, mean
plasma glucose during OGTT (mg/dL); Imean,m e a n
plasma insulin during OGTT (mIU/L)
HOMA-IR:
HOMA - IR =
Glucose × Insulin
405
HOMA-B:
HOMA − β =
360 × Insulin
Glucose - 63
%
Additionally, secondary laboratory outcomes were
measured, including enzymatic tests for total cholesterol,
high density lipoprotein (HDL), calculated low density
lipoprotein (CLDL), and triglycerides. Analysis of C-
reactive protein (CRP) was completed by latex immuno-
turbidimetry, of C-Peptide by radioimmunoassay (Sie-
mens, Los Angeles, CA, USA) and of IL-6 by
immunoassay (Access Chemluminescent Immunoassay
by Beckman Coulter, Fullerton, CA).
In addition, BMI, blood pressure, and muscle strength
were recorded at the baseline, six- and twelve-week vis-
its. One week after the baseline visit, subjects were con-
tacted by the study team to screen for potential adverse
effects of the HCQ. If any potential HCQ-related events
had occurred, the principal investigator was immediately
notified and the subject was contacted. Three weeks fol-
lowing baseline, subjects had an in-person safety inter-
view with a member of the study team to further screen
for potential adverse effects of HCQ; BMI, blood pres-
sure, and muscle strength were all once again recorded.
At six weeks after baseline, subjects returned for their
second OGTT, as well as measurement of secondary
outcomes, BMI, blood pressure, and muscle strength
screening. At nine weeks after baseline, a second phone
conversation was conducted to screen for any other
effects since stopping HCQ. Finally, twelve weeks after
baseline subjects underwent their final OGTT, as well as
Mercer et al. Arthritis Research & Therapy 2012, 14:R135
http://arthritis-research.com/content/14/3/R135
Page 2 of 7secondary laboratory outcome measures, BMI, blood
pressure, and muscle strength screening.
Statistical analyses
Descriptive statistics such as minimum, maximum, range,
median and interquartile range (IQR) were used to
describe the primary outcome (ISI) and secondary out-
comes. The primary outcome, change in ISI levels, was
calculated by comparing pre-treatment (baseline) with
and during treatment (week 6), and between week 0 and
week 12 using Wilcoxon signed-rank tests. Similar ana-
lyses were conducted for HOMA-IR and the secondary
laboratory outcomes. All P-values were calculated with a
two-sided significance level of 0.05. Data analyses were
performed using SAS 9.1.2 (SAS Institute, Inc, Cary,
North Carolina).
Results
Of the 111 potential subjects who underwent pre-
screening, 37 were interested and pursued formal
screening, and 13 of the 37 subjects met the inclusion
criteria and followed through with all study visits. Sub-
jects who were excluded after formal screening included
17 who decided not to participate, 3 who were not eligi-
ble, 3 who did not meet the laboratory or medical
screening criteria, and 1 who did not pass the baseline
eye screening.
Among the 13 enrolled subjects, the median age was
49 years with participants ranging in age from 24 to 71.
The 13 participants included 10 women. The median
BMI of the subjects was 36.1 kg/m
2. Baseline character-
istics were within the normal range for laboratory para-
meters (Table 1).
The median (IQR) increase in ISI during HCQ treat-
ment between baseline and week 6 was from 4.5 (2.3 to
7.8) to 8.9 (3.7 to 11.4) with a P-value of 0.040 (Figure 1a).
We observed a return toward baseline in ISI by week 12
(P = 0.45 comparing baseline to week 12). HOMA-IR was
also examined, and decreased during HCQ treatment
between baseline and week 6 from a median of 2.1 (1.6 to
5.4) to 1.8 (1.02 to 2.1) with a P-value of 0.09 (Figure 1b),
but this decrease was not statistically significant. Between
week 0 and week 12 (post-HCQ), HOMA-IR trended back
towards baseline (P = 0.64 comparing baseline and week
12). The areas under the curve for glucose and insulin
were plotted (Figure 2) and showed stability for glucose,
but reductions in insulin at week 6 during HCQ.
For measurement of the secondary outcomes, we found
small differences between weeks 6 and 12 for total choles-
terol, CLDL and HDL. However, no differences were
observed in CRP, C-peptide, or IL-6 (Table 2).
Discussion
This pilot intervention study demonstrates that six weeks
of HCQ treatment improves insulin sensitivity in obese
non-diabetic subjects without a known systemic inflam-
matory condition. Animal models, randomized controlled
clinical trials, and two epidemiologic studies have all
shown that HCQ positively affects insulin and glucose
metabolism [15-21]. We found a statistically significant
increase in ISI after 6 weeks of HCQ and a decrease in
ISI toward baseline after stopping HCQ. The area under
the curve analysis agrees with the ISI analysis, in that less
insulin maintained similar serum glucose levels. Reduc-
tion in HOMA-IR during HCQ also suggests improved
insulin sensitivity, in that less insulin was required to
control glucose at week 6. Statistical significance was not
established for these results, but the small sample size
could have produced a false negative error. There were
no important changes in secondary outcomes, such as
CRP or IL-6, during this short-term study, and BMI was
consistent.
While this pilot study does not allow us to determine
the clinical relevance of HCQ’s effect on insulin sensitiv-
ity, this degree of improvement in insulin sensitivity may
translate into a reduced risk of DM, as suggested by two
Table 1 Baseline characteristics of thirteen study subjects
Mean (± standard deviation) or median (interquartile range)
Age, years 49 (± 15)
Female gender 77%
Body mass index, kg/m
2 36.1 (30.7 - 38.4)
Blood pressure, diastolic 121.5 (± 5.2)
Blood pressure, systolic 74.7 (± 7.1)
Serum glucose, mg/dl 92 (77 - 95)
Serum insulin, μIU/mL 10.44 (6.89-22.7)
Total cholesterol, mg/dL 165 (146 - 181)
Low density lipoprotein cholesterol, mg/dL 91 (79 -120)
High density lipoprotein, mg/dL 45 (39 - 57)
Triglycerides, mg/dL 85 (64 - 98)
C-reactive protein, mg/L 2.80 (1.3-4.6)
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matoid arthritis [18,19]. While we did not study subjects
with rheumatic disease, we did look at obese individuals
with increased baseline insulin resistance and an ele-
vated baseline CRP, similar to persons with rheumatic
disease. With HCQ’s benefit as a disease-modifying
Panel A.
Panel B. 
Figure 1 Insulin sensitivity and insulin resistance. This figure depicts values for (A) the Insulin Sensitivity Index (ISI), and (B) the homeostasis
model assessment-estimated insulin resistance (HOMA-IR) for each of the 13 study subjects at baseline, 6 weeks, and 12 weeks. Medians are also
indicated as the bars with adjacent values.
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Figure 2 Area under the curve, glucose. This figure illustrates the area under the curve (AUC) for (A)g l u c o s ea n d( B) insulin, during the oral
glucose tolerance tests at weeks 0, 6, and 12. The AUC for glucose was 240 ± 88 (week 0), 232 ± 92 (week 6) and 227 ± 71 (week 12). The
differences in AUC for glucose were not statistically significant (week 0 to week 6, P = 0.45, and week 6 to week 12, P = 0.89). The AUC for
insulin was 134 ±125 (week 0), 95 ± 91 (week 6) and 123 ± 91 (week 12). The differences in AUC for insulin between week 0 to week 6 (P =
0.09) and week 6 to week 12 (P = 0.021) suggest an important trend.
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in persons with rheumatic disease, it may be beneficial
to maintain HCQ use in the rheumatic disease
population.
The small sample size and short duration of drug
administration limits this study, which should be viewed
as hypothesis generating. Also, in Figures 1a and 1b, two
different study subjects who were potential outliers were
included in the statistical analysis, and the results
remained statistically significant. It is important to take
note of these skewed data points, even though it cannot be
determined whether they are due to individualized
responses to HCQ or the possibility that the subject may
not have fasted before testing despite affirming to the
study staff that they had.
The use of the Matsuda ISI as a surrogate measure for a
clinical outcome, such as DM, is another limitation of this
study. However, a paper on the current approaches to
measuring insulin sensitivity suggests that the Matsuda ISI
is highly correlated with results from the gold standard of
metabolic testing, the euglycemic insulin clamp [24]. Addi-
tionally, the Matsuda ISI provides a dynamic measure for
analyzing both glucose uptake and insulin secretion in
response to a challenge, and has proved to be an accurate
predictor of DM in epidemiologic studies [24]. Clinical
studies among a variety of patient populations including
those with DM, obesity, and stroke have successfully used
ISI to evaluate a change in insulin sensitivity after under-
going drug treatment [25-29]. Studies using metformin,
moxonidine, glyburide, glargine insulin, rosiglitazone and
pioglitazone have reported changes in ISI ranging from
0.14 to 1.18 after treatment [25-29]. In this study, even lar-
ger changes in ISI after HCQ treatment were reported.
In this small pilot study we found that during HCQ
use, obese non-diabetic subjects experienced a significant
benefit in insulin sensitivity. No concurrent evidence of
improvement in inflammatory markers was observed (for
example, CRP and IL-6 did not change). This argues for
a direct effect of HCQ on insulin metabolism-reduced
degradation or enhanced activity at the receptor level,
rather than an indirect effect through reduced inflamma-
tion. An important next step in this line of investigation
w o u l db eal a r g e ra n dl o n g e rs t u d ye x a m i n i n gt h ee f f e c t
of HCQ on insulin sensitivity, focusing on subjects with
systemic inflammatory conditions, a population at an
increased risk for insulin resistance and DM [30,31]. If
HCQ improves insulin sensitivity in people with systema-
tic rheumatic disease, a diabetes prevention trial should
be considered for high risk patients with RA or SLE.
Additional material
Additional File 1: Appendix Table 1 Schedule of study visits and
phone calls. A descriptive table of all study visits and data collected at
each visit. Microsoft Word 3 column table.
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